EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Newsletter

What is the implementation timetable?

Dose Diligence research deskSection 10 · Page 13 of 15Last updated 17 Nov 2026

Recommended management milestones—not external deadlines.

TimingDecisionRequired output
By December 15, 2026Which arrangements are sufficiently evidenced to model?Product–entity–state register and unresolved-issue list
Before January commitmentsWhich price and eligibility assumptions remain valid?Dated quotation and programme-term refresh
January 2027Can the preferred route work in practice?Controlled pilot with defined stop/go criteria
February 2027Is the alternative route usable?Tested escalation and transition exercise
March 2027What should scale, change or stop?Review of fulfilment, cost, complaints and concentration

Bottom line: Approve a route only when the team can explain who supplies, who dispenses, who pays, what evidence supports the arrangement and how patients will be supported if it fails.

This outlook is decision support, not a legal opinion, treatment recommendation or guarantee of savings.

Explore the table row by row

A working view of the research

By December 15, 2026

Decision
Which arrangements are sufficiently evidenced to model?
Required output
Product–entity–state register and unresolved-issue list

Sources cited on this page

    See the section’s source register for the research context.

    Section sources →